-
1.
公开(公告)号:US20180028442A1
公开(公告)日:2018-02-01
申请号:US15616103
申请日:2017-06-07
申请人: TargaGenix, Inc. , The Research Foundation for the State University New York , Northeastern University
IPC分类号: A61K9/107 , A61K31/337 , A61K9/51 , A61K47/12
CPC分类号: A61K9/1075 , A61K9/51 , A61K31/337 , A61K47/12 , A61K47/44
摘要: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.
-
公开(公告)号:US20170190760A1
公开(公告)日:2017-07-06
申请号:US15347931
申请日:2016-11-10
发明人: Srinivas Pentyala
IPC分类号: C07K14/72
CPC分类号: C07K14/723 , A61K38/00 , A61K38/10 , C07K7/08 , C07K14/705
摘要: The present invention is based, in part, on our discovery of compositions and methods that can be used to treat a patient who has a compromised bone (due, for example, to a disease such as osteoporosis or an injury such as a bone fracture). The compositions can also be administered prophylactically. For example, they can be administered to help maintain bone health as a patient ages. More specifically, the compositions include polypeptides that constitute (or that include) a fragment of a calcitonin receptor (CR) and polypeptides that constitute (or include) biologically active variants of those fragments. Sequence-specific formulas are provided herein. Related U.S. Application Data and polypeptides conforming to those formulas, as well as nucleic acids encoding them, expression vectors, host cells, pharmaceutical formulations, and methods of their preparation and use are within the scope of the present invention.
-
公开(公告)号:US20150001088A1
公开(公告)日:2015-01-01
申请号:US14375157
申请日:2013-02-08
CPC分类号: C25D15/00 , B22F1/0018 , B22F9/24 , B22F2999/00 , B82Y40/00 , C25D13/22 , C25D15/02
摘要: A method of synthesizing metal nanoparticles is provided. The method includes submerging an electrically conductive substrate in a polysaccharide solution containing a predetermined concentration of a metal salt; applying an electric potential between the electrically conductive substrate and the polysaccharide solution for a predetermined period of time to form a polysaccharide layer containing metal nanoparticles on the electrically conductive substrate; re-dissolving the polysaccharide layer in a solvent to form a solution including the polysaccharide and the metal nanoparticles; and separating the metal nanoparticles from the polysaccharide.
摘要翻译: 提供合成金属纳米粒子的方法。 该方法包括将导电基底浸入含有预定浓度的金属盐的多糖溶液中; 在导电性基材和多糖溶液之间施加电位达预定时间,以在导电性基材上形成含有金属纳米粒子的多糖层; 将多糖层再溶解在溶剂中以形成包含多糖和金属纳米颗粒的溶液; 并将金属纳米颗粒与多糖分离。
-
公开(公告)号:US20210088699A1
公开(公告)日:2021-03-25
申请号:US15948475
申请日:2018-04-09
申请人: Ngwe Thawdar , Michael Medley , The Research Foundation for The State University New York , The Research Foundation of CUNY
摘要: A plasmonic phase modulator is provided. The modulator has a conductive layer, and a dielectric layer disposed on the conductive layer. A plasmonic layer is disposed on the dielectric layer. A plasmonic layer is disposed on the dielectric layer. The plasmonic layer is conductive to surface plasmon polariton (SPP) waves. The plasmonic layer may be, for example, a graphene sheet. A voltage signal source is operatively connected between the conductive layer and the plasmonic layer for modulating a propagation speed of an SPP wave propagating on the plasmonic layer.
-
公开(公告)号:US20160129017A1
公开(公告)日:2016-05-12
申请号:US14900719
申请日:2014-07-01
发明人: William G. KERR , Sonia IYER
IPC分类号: A61K31/575 , A61K31/568 , A61K31/4709 , A61K31/5685 , A61K31/473 , A61K31/4045 , C12N15/113 , A61K31/655
CPC分类号: A61K31/575 , A61K31/4045 , A61K31/4709 , A61K31/473 , A61K31/565 , A61K31/566 , A61K31/568 , A61K31/5685 , A61K31/655 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/141
摘要: The present invention relates to the use of SHIP1 inhibitors and pan-SHIP1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol.
摘要翻译: 本发明涉及SHIP1抑制剂和pan-SHIP1 / 2抑制剂在各种方法中的应用,包括但不限于:(i)一种治疗肥胖或降低肥胖受试者体重的方法; (ii)限制患有骨质疏松症或硬化性疾病的受试者的骨发育的方法; (iii)治疗或预防糖尿病的方法; (iv)降低葡萄糖不耐受或胰岛素抵抗的方法; 和(v)降低胆固醇的方法。
-
公开(公告)号:US20150246908A1
公开(公告)日:2015-09-03
申请号:US14417396
申请日:2013-07-26
发明人: Thomas D. Bannister , Yuanjun He , Agnieszka Bialkowska , Vincent Yang , Melissa Crisp , Peter Hodder
IPC分类号: C07D417/12 , C07D333/48 , C07D409/12 , C07D335/00
CPC分类号: C07D417/12 , C07D333/48 , C07D335/00 , C07D335/02 , C07D409/12
摘要: The invention provides potent inhibitors of small molecule inhibitors of Krüppel-like factor 5 (KLF5) expression. Compounds of the invention are small molecule inhibitors of KLF5 expression which can be effective delay or prevent colon cancer onset, halt growth of existing tumors, and/or decrease reoccurrence. The compounds can be effective vs. many tumor types whose progression is in part mediated by KLF5, including colorectal cancers. Lowering KLF5 levels with an inhibitor of this invention may also impact other disease states, including diabetes, obesity, lipid homeostasis, cardiovascular disease, and arthritis.
摘要翻译: 本发明提供Krüppel样因子5(KLF5)表达的小分子抑制剂的有效抑制剂。 本发明的化合物是KLF5表达的小分子抑制剂,其可以有效延迟或预防结肠癌发病,停止现有肿瘤的生长和/或减少再发生。 该化合物对许多肿瘤类型有效,其进展部分由KLF5介导,包括结肠直肠癌。 用本发明抑制剂降低KLF5水平也可能影响其他疾病状态,包括糖尿病,肥胖,脂质体内平衡,心血管疾病和关节炎。
-
公开(公告)号:US20180012137A1
公开(公告)日:2018-01-11
申请号:US15359122
申请日:2016-11-22
发明人: Robert Wright , Lei Yu , Steven Loscalzo
CPC分类号: G06N7/005 , G05B13/0265 , G05B15/02 , G06N20/00 , Y02B10/30
摘要: A control system and method for controlling a system, which employs a data set representing a plurality of states and associated trajectories of an environment of the system; and which iteratively determines an estimate of an optimal control policy for the system. The iterative process performs the substeps, until convergence, of estimating a long term value for operation at a respective state of the environment over a series of predicted future environmental states; using a complex return of the data set to determine a bound to improve the estimated long term value; and producing an updated estimate of an optimal control policy dependent on the improved estimate of the long term value. The control system may produce an output signal to control the system directly, or output the optimized control policy. The system preferably is a reinforcement learning system which continually improves.
-
公开(公告)号:USRE50096E1
公开(公告)日:2024-08-27
申请号:US17179720
申请日:2021-02-19
申请人: TargaGenix, Inc. , The Research Foundation for the State University New York , Northeastern University
CPC分类号: A61K9/1075 , A61K9/51 , A61K31/337 , A61K47/12 , A61K47/44 , A61K47/542 , A61K47/6907
摘要: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.
-
-
-
-
-
-
-